Premier Alternatives

Angiocrine Bioscience

San Diego, CA · Founded 2012 · Privately Held (backing)

Developer of a curative cellular therapies platform designed to treat indications in regenerative medicine and hematopoietic stem cell gene therapy. Angiocrine Bioscience is based in San Diego, CA and was founded in 2012. It was valued at $25.1 million at its later-stage round in Sep 2025, the last priced event on record. It has raised $88.8 million across 2 recorded rounds; the latest was a $2.1 million seed round in Aug 2025.

PMV mark · valuation
$25.1M
Oct 2026
Priced at
its later-stage round
Sep 2025
Total raised
$88.8M
Last round
Seed Round
Aug 2025

Angiocrine Bioscience key facts

as of Oct 2026
  • Developer of a curative cellular therapies platform designed to treat indications in regenerative medicine and hematopoietic stem cell gene therapy.
  • Angiocrine Bioscience is valued at approximately $25.1M as of Oct 2026, set at its later-stage round, Sep 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $88.8M across 2 recorded rounds; the latest was Seed Round ($2.1M) in Aug 2025.
  • Notable investors include Good Growth Capital, Dubin & Co., Axil Capital Partners, California Institute for Regenerative Medicine, Cobro Ventures — 7 tracked in total.
  • Angiocrine Bioscience has filed 2 Form Ds with the SEC since 2021, most recently Sep 2025 ($2.1M sold to 16 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$25.1M

Valued at $25.1M at its later-stage round, Sep 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Angiocrine Bioscience with a free account
  • ·Watch Angiocrine Bioscience: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Angiocrine Bioscience funding rounds

2 rounds
Aug 2025Seed Round$2.1MSEC filing▮
Oct 2021Later Stage VC$58.1MSEC filing▮
Full funding history →

Angiocrine Bioscience valuation

Angiocrine Bioscience was valued at $25.1 million at its later-stage round in Sep 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Angiocrine Bioscience raised?

Angiocrine Bioscience has raised $88.8 million in total; 2 of its rounds are on record. The largest on record was a $58.1 million later-stage round in Oct 2021; the most recent was a $2.1 million seed round in Aug 2025.

Angiocrine Bioscience has filed 2 Form Ds with the SEC since 2021, most recently in Sep 2025 ($2.1 million sold to 16 investors).

Angiocrine Bioscience investors

7 investors are on record for Angiocrine Bioscience, including Good Growth Capital, Dubin & Co., Axil Capital Partners and California Institute for Regenerative Medicine. The seed round in Aug 2025 drew 16 investors.

About Angiocrine Bioscience

Developer of a curative cellular therapies platform designed to treat indications in regenerative medicine and hematopoietic stem cell gene therapy. The company's platform comprises cultured endothelial cells that are genetically modified via insertion of the adenovirus gene, enabling physicians to improvise their treatment and therapeutic procedures.

Sector
Healthcare
HQ
San Diego, CA, United States
Founded
2012
Employees
15
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.